Mylan Inc. (Nasdaq: MYL) has announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company for $550 million in cash.
Original Source of Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
@FiercePharma:
Sanofi-Aventis is moving work around–and the changes are claiming jobs. As Pharmalot reports, the French drugmaker is shifting laboratory and regulatory affairs work from Great Valley, PA, to other locations, putting 400 employees and 200 contract workers in jeopardy. Meanwhile, a pilot plant in Bridgewater, NJ, is slated for…
Novartis has conceded the fight with its female employees . The Swiss drugmaker agreed to pay up to $175 million to settle a high-profile gender discrimination lawsuit, ending a battle that put Novartis managers’ misbehavior in the headlines.
Has the Federal Trade Commission overstepped its bounds? U.S. Judge Alan Kay suspects so, after hearing evidence in a
It’s legal wrap-up week for GlaxoSmithKline. First, the company agreed to settle
The European Medicines Agency has started a review of the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim, to determine whether new data on the risk of cardiovascular problems have an impact on their benefit-risk profile.
Original Source of European Medicines Agency starts review of rosiglitazone-containing medicines
The Amgen Foundation is supporting an online competition with Ashoka’s Changemakers to find the best solutions that elevate patients’ voices to improve health outcomes globally.
Original Source of Amgen Foundation and Changemakers Launch Global Online Competition to Empower Patients
After two days of deliberation, we saw a mixed vote on Avandia . Twelve members voted to take off the market, while 17 recommended changing the label to various degrees. Three
The votes are in, and it isn’t good news for GlaxoSmithKline’s ( NYSE: GSK ) Avandia (rosiglitazone). Twelve members of an FDA panel voted to recommend market withdrawal; 10 others voted for continued marketing with restrictions on use and revised label and seven to revise current labels to add…